

Perth, Australia, 3 December 2018: BARD1 Life Sciences Limited (BARD1 LSL or Company) (ASX:BD1), advises that Executive Director, Dr Irmgard Irminger-Finger, has sold 8,599,683 shares in the Company as detailed in the attached Appendix 3Y.

Dr Irminger-Finger, who is the Company's largest shareholder, has advised that she has sold the shares to enable her to participate in the Company's non-renounceable rights issue which was announced on 08/11/2018.

Pauline Collinson
Company Secretary

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian-based biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1's proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The development pipeline includes two BARD1 autoantibody tests in early development for early detection of lung and ovarian cancers, and a cancer vaccine project at research-stage for treatment of cancer. Additional diagnostic projects are being evaluated for prostate, breast and other cancers. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients' lives. For more information on BARD1, see www.bard1.com.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	BARD1 LIFE SCIENCES LIMITED
ABN	58 009 070 384

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	IRMGARD IRMINGER-FINGER
Date of last notice	16 JUNE 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	DIRECT
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	27 – 29 November 2018
No. of securities held prior to change	108,252,420 Ordinary Shares 108,252,420 Performance Shares with an expiry date of 5 years from the date of issue.
Class	Ordinary Shares
Number acquired	Nil
Number disposed	8,599,683
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$204,981.51 (includes brokerage fees)
No. of securities held after change	99,652,737 Ordinary Shares 108,252,420 Performance Shares with an expiry date of 5 years from the date of issue.

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-Market Trades
---	------------------

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.